{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:26:40Z","timestamp":1784759200463,"version":"3.55.0"},"reference-count":229,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T00:00:00Z","timestamp":1476662400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Can J Anesth\/J Can Anesth"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s12630-016-0748-1","type":"journal-article","created":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T18:20:16Z","timestamp":1476728416000},"page":"45-64","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Pharmacogenomics and pharmacogenetics for the intensive care unit: a narrative review","Utilisation de la pharmacog\u00e9nomique et de la pharmacog\u00e9n\u00e9tique \u00e0 l\u2019unit\u00e9 de soins intensifs: un compte rendu narratif"],"prefix":"10.1007","volume":"64","author":[{"given":"Meghan","family":"MacKenzie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7666-889X","authenticated-orcid":false,"given":"Richard","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,17]]},"reference":[{"key":"748_CR1","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/35057062","volume":"409","author":"ES Lander","year":"2001","unstructured":"Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.","journal-title":"Nature"},{"key":"748_CR2","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1126\/science.1058040","volume":"291","author":"JC Venter","year":"2001","unstructured":"Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001; 291: 1304-51.","journal-title":"Science"},{"key":"748_CR3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0167-7799(01)01814-5","volume":"19","author":"GS Ginsburg","year":"2001","unstructured":"Ginsburg GS, McCarthy JJ. Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol 2001; 19: 491-6.","journal-title":"Trends Biotechnol"},{"key":"748_CR4","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/35015728","volume":"405","author":"AD Roses","year":"2000","unstructured":"Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000; 405: 857-65.","journal-title":"Nature"},{"key":"748_CR5","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMsb1503104","volume":"372","author":"JL Jameson","year":"2015","unstructured":"Jameson JL, Longo DL. Precision medicine-personalized, problematic, and promising. N Engl J Med 2015; 372: 2229-34.","journal-title":"N Engl J Med"},{"key":"748_CR6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.31887\/DCNS.2004.6.1\/mhoehe","volume":"6","author":"MR Hoehe","year":"2004","unstructured":"Hoehe MR, Kroslak T. Genetic variation and pharmacogenomics: concepts, facts, and challenges. Dialogues Clin Neurosci 2004; 6: 5-26.","journal-title":"Dialogues Clin Neurosci"},{"key":"748_CR7","first-page":"751","volume":"3","author":"RA McKinnon","year":"2007","unstructured":"McKinnon RA, Ward MB, Sorich MJ. A critical analysis of barriers to the clinical implementation of pharmacogenomics. Ther Clin Risk Manag 2007; 3: 751-9.","journal-title":"Ther Clin Risk Manag"},{"key":"748_CR8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-62703-435-7_1","volume":"1015","author":"R Charlab","year":"2013","unstructured":"Charlab R, Zhang L. Pharmacogenomics: historical perspective and current status. Methods Mol Biol 2013; 1015: 3-22.","journal-title":"Methods Mol Biol"},{"key":"748_CR9","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.drudis.2011.08.006","volume":"16","author":"M Pirmohamed","year":"2011","unstructured":"Pirmohamed M. Pharmacogenetics: past, present and future. Drug Discov Today 2011; 16: 852-61.","journal-title":"Drug Discov Today"},{"key":"748_CR10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature15817","volume":"526","author":"MV Relling","year":"2015","unstructured":"Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature 2015; 526: 343-50.","journal-title":"Nature"},{"key":"748_CR11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s00109-002-0417-4","volume":"81","author":"C Meisel","year":"2003","unstructured":"Meisel C, Gerloff T, Kirchheiner J, et al. Implications of pharmacogenetics for individualizing drug treatment and for study design. J Mol Med (Berl) 2003; 81: 154-67.","journal-title":"J Mol Med (Berl)"},{"key":"748_CR12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/138920210791110951","volume":"11","author":"RE Ellsworth","year":"2010","unstructured":"Ellsworth RE, Decewicz DJ, Shriver CD, Ellsworth DL. Breast cancer in the personal genomics era. Curr Genomics 2010; 11: 146-61.","journal-title":"Curr Genomics"},{"key":"748_CR13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jama.2016.8662","volume":"316","author":"Y Wang","year":"2016","unstructured":"Wang Y, Zhao X, Lin J, et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA 2016; 316: 70-8.","journal-title":"JAMA"},{"key":"748_CR14","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1161\/01.CIR.101.12.1366","volume":"101","author":"LU Gerdes","year":"2000","unstructured":"Gerdes LU, Gerdes C, Kervinen K, et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation 2000; 101: 1366-71.","journal-title":"Circulation"},{"key":"748_CR15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bpa.2007.09.005","volume":"22","author":"DA Schwinn","year":"2008","unstructured":"Schwinn DA, Podgoreanu M. Pharmacogenomics and end-organ susceptibility to injury in the perioperative period. Best Pract Res Clin Anaesthesiol 2008; 22: 23-37.","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"748_CR16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0378-4274(01)00280-6","volume":"120","author":"BK Park","year":"2001","unstructured":"Park BK, Pirmohamed M. Toxicogenetics in drug development. Toxicol Lett 2001; 120: 281-91.","journal-title":"Toxicol Lett"},{"key":"748_CR17","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1055\/s-0035-1564852","volume":"36","author":"AM Ahasic","year":"2015","unstructured":"Ahasic AM, Christiani DC. Personalized critical care medicine: how far away are we? Semin Respir Crit Care Med 2015; 36: 809-22.","journal-title":"Semin Respir Crit Care Med"},{"key":"748_CR18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/cpt.294","volume":"99","author":"DL Hertz","year":"2016","unstructured":"Hertz DL, McLeod HL. Integrated patient and tumor genetic testing for individualized cancer therapy. Clinical Pharmacol Ther 2016; 99: 143-6.","journal-title":"Clinical Pharmacol Ther"},{"key":"748_CR19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1146\/annurev.genom.2.1.9","volume":"2","author":"WE Evans","year":"2001","unstructured":"Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001; 2: 9-39.","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"748_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-med-011209-132719","volume":"61","author":"CT Caskey","year":"2010","unstructured":"Caskey CT. Using genetic diagnosis to determine individual therapeutic utility. Annu Rev Med 2010; 61: 1-15.","journal-title":"Annu Rev Med"},{"key":"748_CR21","doi-asserted-by":"crossref","first-page":"E29","DOI":"10.1208\/ps020329","volume":"2","author":"DL Veenstra","year":"2000","unstructured":"Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci 2000; 2: E29.","journal-title":"AAPS PharmSci"},{"key":"748_CR22","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2165\/00003088-200140110-00001","volume":"40","author":"MH Ensom","year":"2001","unstructured":"Ensom MH, Chang TK, Patel P. Pharmacogenetics: the therapeutic drug monitoring of the future? Clin Pharmacokinet 2001; 40: 783-802.","journal-title":"Clin Pharmacokinet"},{"key":"748_CR23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2174\/1872208309666140904111139","volume":"8","author":"JM Allen","year":"2014","unstructured":"Allen JM, Gelot S. Pharmacogenomics in the intensive care unit: focus on potential implications for clinical practice. Recent Pat Biotechnol 2014; 8: 116-22.","journal-title":"Recent Pat Biotechnol"},{"key":"748_CR24","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(12)60161-5","volume":"379","author":"JD Roberts","year":"2012","unstructured":"Roberts JD, Wells GA, Le May MR, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 2012; 379: 1705-11.","journal-title":"Lancet"},{"key":"748_CR25","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMoa1311386","volume":"369","author":"M Pirmohamed","year":"2013","unstructured":"Pirmohamed M, Burnside G, Eriksson N, et al. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013; 369: 2294-303.","journal-title":"N Engl J Med"},{"key":"748_CR26","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1517\/17425255.2013.799137","volume":"9","author":"DJ Roberts","year":"2013","unstructured":"Roberts DJ, Hall RI. Drug absorption, distribution, metabolism and excretion considerations in critically ill adults. Expert Opin Drug Metab Toxicol 2013; 9: 1067-84.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"748_CR27","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1517\/14656566.6.15.2565","volume":"6","author":"R Mango","year":"2005","unstructured":"Mango R, Vecchione L, Raso B, et al. Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy. Expert Opin Pharmacother 2005; 6: 2565-76.","journal-title":"Expert Opin Pharmacother"},{"key":"748_CR28","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1124\/pr.58.3.6","volume":"58","author":"SJ Gardiner","year":"2006","unstructured":"Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006; 58: 521-90.","journal-title":"Pharmacol Rev"},{"key":"748_CR29","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2044.2004.03570.x","volume":"59","author":"BP Sweeney","year":"2004","unstructured":"Sweeney BP. Watson and Crick 50 years on. From double helix to pharmacogenomics. Anaesthesia 2004; 59: 150-65.","journal-title":"Anaesthesia"},{"key":"748_CR30","first-page":"2550","volume":"87","author":"CH Evans","year":"2005","unstructured":"Evans CH, Rosier RN. Molecular biology in orthopaedics: the advent of molecular orthopaedics. J Bone Joint Surg Am 2005; 87: 2550-64.","journal-title":"J Bone Joint Surg Am"},{"key":"748_CR31","first-page":"140","volume":"45","author":"TH Fagerlund","year":"2001","unstructured":"Fagerlund TH, Braaten O. No pain relief from codeine\u2026? An introduction to pharmacogenomics. Acta Anaesthesiol Scand 2001; 45: 140-9.","journal-title":"Acta Anaesthesiol Scand"},{"key":"748_CR32","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/cc12693","volume":"17","author":"S Skibsted","year":"2013","unstructured":"Skibsted S, Bhasin MK, Aird WC, Shapiro NI. Bench-to-bedside review: future novel diagnostics for sepsis - a systems biology approach. Crit Care 2013; 17: 231.","journal-title":"Crit Care"},{"key":"748_CR33","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","volume":"116","author":"M Ingelman-Sundberg","year":"2007","unstructured":"Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116: 496-526.","journal-title":"Pharmacol Ther"},{"key":"748_CR34","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1164\/ajrccm.165.7.2109096","volume":"165","author":"LJ Palmer","year":"2002","unstructured":"Palmer LJ, Silverman ES, Weiss ST, Drazen JM. Pharmacogenetics of asthma. Am J Respir Crit Care Med 2002; 165: 861-6.","journal-title":"Am J Respir Crit Care Med"},{"key":"748_CR35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1081\/DMR-100102341","volume":"32","author":"T Arledge","year":"2000","unstructured":"Arledge T, Freeman A, Arbuckle J, Mosteller M, Manasco P. Applications of pharmacogenetics to drug development: the Glaxo Wellcome experience. Drug Metab Rev 2000; 32: 387-94.","journal-title":"Drug Metab Rev"},{"key":"748_CR36","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s12975-012-0229-y","volume":"4","author":"LJ Mawhinney","year":"2013","unstructured":"Mawhinney LJ, Mabourakh D, Lewis MC. Gender-specific differences in the central nervous system\u2019s response to anesthesia. Transl Stroke Res 2013; 4: 462-75.","journal-title":"Transl Stroke Res"},{"key":"748_CR37","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1517\/17425255.2015.1004310","volume":"11","author":"E Reeve","year":"2015","unstructured":"Reeve E, Wiese MD, Mangoni AA. Alterations in drug disposition in older adults. Expert Opinion Drug Metab Toxicol 2015; 11: 491-508.","journal-title":"Expert Opinion Drug Metab Toxicol"},{"key":"748_CR38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.12968\/hmed.2015.76.2.89","volume":"76","author":"G Tansley","year":"2015","unstructured":"Tansley G, Hall R. Pharmacokinetic considerations for drugs administered in the critically ill. Br J Hosp Med (Lond) 2015; 76: 89-94.","journal-title":"Br J Hosp Med (Lond)"},{"key":"748_CR39","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.amjopharm.2011.10.004","volume":"9","author":"LE Hines","year":"2011","unstructured":"Hines LE, Murphy JE. Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother 2011; 9: 364-77.","journal-title":"Am J Geriatr Pharmacother"},{"key":"748_CR40","first-page":"131","volume":"18","author":"ZY Ren","year":"2015","unstructured":"Ren ZY, Xu XQ, Bao YP, et al. The impact of genetic variation on sensitivity to opioid analgesics in patients with postoperative pain: a systematic review and meta-analysis. Pain Physician 2015; 18: 131-52.","journal-title":"Pain Physician"},{"key":"748_CR41","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1126\/science.134.3489.1530","volume":"134","author":"S Sunahara","year":"1961","unstructured":"Sunahara S, Urano M, Ogawa M. Genetical and geographic studies on isoniazid inactivation. Science 1961; 134: 1530-1.","journal-title":"Science"},{"key":"748_CR42","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/hrt.2004.044560","volume":"91","author":"JM Khan","year":"2005","unstructured":"Khan JM, Beevers DG. Management of hypertension in ethnic minorities. Heart 2005; 91: 1105-9.","journal-title":"Heart"},{"key":"748_CR43","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/clpt.2009.170","volume":"86","author":"AL Birkenfeld","year":"2009","unstructured":"Birkenfeld AL, Jordan J, Hofmann U, et al. Genetic influences on the pharmacokinetics of orally and intravenously administered digoxin as exhibited by monozygotic twins. Clin Pharmacol Ther 2009; 86: 605-8.","journal-title":"Clin Pharmacol Ther"},{"key":"748_CR44","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1001\/jama.286.18.2270","volume":"286","author":"KA Phillips","year":"2001","unstructured":"Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001; 286: 2270-9.","journal-title":"JAMA"},{"key":"748_CR45","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra020021","volume":"348","author":"R Weinshilboum","year":"2003","unstructured":"Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348: 529-37.","journal-title":"N Engl J Med"},{"key":"748_CR46","first-page":"393","volume":"78","author":"T Ama","year":"2010","unstructured":"Ama T, Bounmythavong S, Blaze J, Weismann M, Marienau MS, Nicholson WT. Implications of pharmacogenomics for anesthesia providers. AANA J 2010; 78: 393-9.","journal-title":"AANA J"},{"key":"748_CR47","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1056\/NEJMoa041888","volume":"351","author":"Y Gasche","year":"2004","unstructured":"Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med 2004; 351: 2827-31.","journal-title":"N Engl J Med"},{"key":"748_CR48","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1056\/NEJMra020526","volume":"348","author":"WE Evans","year":"2003","unstructured":"Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-49.","journal-title":"N Engl J Med"},{"key":"748_CR49","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1097\/CCM.0b013e3181b755d5","volume":"37","author":"DJ Roberts","year":"2009","unstructured":"Roberts DJ, Goralski KB, Renton KW, et al. Effect of acute inflammatory brain injury on accumulation of morphine and morphine 3- and 6-glucuronide in the human brain. Crit Care Med 2009; 37: 2767-74.","journal-title":"Crit Care Med"},{"key":"748_CR50","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-1-59745-205-2_8","volume":"448","author":"MD Thompson","year":"2008","unstructured":"Thompson MD, Siminovitch KA, Cole DE. G protein-coupled receptor pharmacogenetics. Methods Mol Biol 2008; 448: 139-85.","journal-title":"Methods Mol Biol"},{"key":"748_CR51","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1186\/s13054-014-0643-5","volume":"18","author":"PA Jolivot","year":"2014","unstructured":"Jolivot PA, Hindlet P, Pichereau C, et al. A systematic review of adult admissions to ICUs related to adverse drug events. Crit Care 2014; 18: 643.","journal-title":"Crit Care"},{"key":"748_CR52","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/cpt.280","volume":"99","author":"LV Kalman","year":"2016","unstructured":"Kalman LV, Agundez J, Appell ML, et al. Pharmacogenetic allele nomenclature: international workgroup recommendations for test result reporting. Clin Pharmacol Ther 2016; 99: 172-85.","journal-title":"Clin Pharmacol Ther"},{"key":"748_CR53","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","volume":"92","author":"M Whirl-Carrillo","year":"2012","unstructured":"Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012; 92: 414-7.","journal-title":"Clin Pharmacol Ther"},{"key":"748_CR54","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/clpt.2010.279","volume":"89","author":"MV Relling","year":"2011","unstructured":"Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 2011; 89: 464-7.","journal-title":"Clin Pharmacol Ther"},{"key":"748_CR55","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrd705","volume":"1","author":"DM Roden","year":"2002","unstructured":"Roden DM, George AL Jr. The genetic basis of variability in drug responses. Nat Rev Drug Discov 2002; 1: 37-44.","journal-title":"Nat Rev Drug Discov"},{"key":"748_CR56","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00228-007-0424-z","volume":"64","author":"J Brockmoller","year":"2008","unstructured":"Brockmoller J, Tzvetkov MV. Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. Eur J Clin Pharmacol 2008; 64: 133-57.","journal-title":"Eur J Clin Pharmacol"},{"key":"748_CR57","first-page":"227","volume":"7","author":"NS Abul-Husn","year":"2014","unstructured":"Abul-Husn NS, Owusu Obeng A, Sanderson SC, Gottesman O, Scott SA. Implementation and utilization of genetic testing in personalized medicine. Pharmgenomics Pers Med 2014; 7: 227-40.","journal-title":"Pharmgenomics Pers Med"},{"key":"748_CR58","first-page":"43","volume":"8","author":"AL Beitelshees","year":"2015","unstructured":"Beitelshees AL, Voora D, Lewis JP. Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics. Pharmgenomics Pers Med 2015; 8: 43-61.","journal-title":"Pharmgenomics Pers Med"},{"key":"748_CR59","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.2165\/11636220-000000000-00000","volume":"72","author":"DJ Roberts","year":"2012","unstructured":"Roberts DJ, Haroon B, Hall RI. Sedation for critically ill or injured adults in the intensive care unit: a shifting paradigm. Drugs 2012; 72: 1881-916.","journal-title":"Drugs"},{"issue":"580-90","key":"748_CR60","first-page":"e28","volume":"170","author":"MD Kertai","year":"2015","unstructured":"Kertai MD, Li YJ, Ji Y, et al. Genome-wide association study of new-onset atrial fibrillation after coronary artery bypass grafting surgery. Am Heart J 2015; 170(580-90): e28.","journal-title":"Am Heart J"},{"key":"748_CR61","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2174\/138920212802510484","volume":"13","author":"V Sawhney","year":"2012","unstructured":"Sawhney V, Brouilette S, Abrams D, Schilling R, O\u2019Brien B. Current genomics in cardiovascular medicine. Curr Genomics 2012; 13: 446-62.","journal-title":"Curr Genomics"},{"key":"748_CR62","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/clpt.2011.371","volume":"92","author":"JM Pulley","year":"2012","unstructured":"Pulley JM, Denny JC, Peterson JF, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther 2012; 92: 87-95.","journal-title":"Clin Pharmacol Ther"},{"key":"748_CR63","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/clpt.2011.34","volume":"89","author":"JJ Swen","year":"2011","unstructured":"Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte - an update of guidelines. Clin Pharmacol Ther 2011; 89: 662-73.","journal-title":"Clin Pharmacol Ther"},{"key":"748_CR64","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/j.1875-9114.1998.tb03830.x","volume":"18","author":"EL Michalets","year":"1998","unstructured":"Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18: 84-112.","journal-title":"Pharmacotherapy"},{"key":"748_CR65","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.287.13.1690","volume":"287","author":"MK Higashi","year":"2002","unstructured":"Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-8.","journal-title":"JAMA"},{"key":"748_CR66","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00023210-200721020-00005","volume":"21","author":"MW Mann","year":"2007","unstructured":"Mann MW, Pons G. Various pharmacogenetic aspects of antiepileptic drug therapy: a review. CNS Drugs 2007; 21: 143-64.","journal-title":"CNS Drugs"},{"key":"748_CR67","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0009-9236(01)95478-5","volume":"70","author":"R Brandolese","year":"2001","unstructured":"Brandolese R, Scordo MG, Spina E, Gusella M, Padrini R. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin Pharmacol Ther 2001; 70: 391-4.","journal-title":"Clin Pharmacol Ther"},{"key":"748_CR68","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/icvts\/ivs483","volume":"16","author":"AJ Patel","year":"2013","unstructured":"Patel AJ, Som R. What is the optimum prophylaxis against gastrointestinal haemorrhage for patients undergoing adult cardiac surgery: histamine receptor antagonists, or proton-pump inhibitors? Interact Cardiovasc Thorac Surg 2013; 16: 356-60.","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"748_CR69","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/0091270009333016","volume":"49","author":"BL Chen","year":"2009","unstructured":"Chen BL, Chen Y, Tu JH, et al. Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms. J Clin Pharmacol 2009; 49: 574-81.","journal-title":"J Clin Pharmacol"},{"key":"748_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.26325","author":"GN Levine","year":"2015","unstructured":"Levine GN, Bates ER, Blankenship JC, et al. ACC\/AHA\/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF\/AHA Guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2015. DOI: 10.1002\/ccd.26325 .","journal-title":"J Am Coll Cardiol"},{"key":"748_CR71","doi-asserted-by":"crossref","first-page":"d3488","DOI":"10.1136\/bmj.d3488","volume":"342","author":"G Passacquale","year":"2011","unstructured":"Passacquale G, Ferro A. Oral antiplatelet agents clopidogrel and prasugrel for the prevention of cardiovascular events. BMJ 2011; 342: d3488.","journal-title":"BMJ"},{"key":"748_CR72","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1046\/j.0007-1323.2001.01774.x","volume":"88","author":"P Robless","year":"2001","unstructured":"Robless P, Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 2001; 88: 787-800.","journal-title":"Br J Surg"},{"key":"748_CR73","doi-asserted-by":"crossref","first-page":"e0132561","DOI":"10.1371\/journal.pone.0132561","volume":"10","author":"YQ Wei","year":"2015","unstructured":"Wei YQ, Wang DG, Yang H, Cao H. Cytochrome P450 CYP 2C19*2 associated with adverse 1-year cardiovascular events in patients with acute coronary syndrome. PloS One 2015; 10: e0132561.","journal-title":"PloS One"},{"key":"748_CR74","doi-asserted-by":"crossref","first-page":"e001652","DOI":"10.1161\/JAHA.114.001652","volume":"4","author":"CW McDonough","year":"2015","unstructured":"McDonough CW, McClure LA, Mitchell BD, et al. CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study. J Am Heart Assoc 2015; 4: e001652.","journal-title":"J Am Heart Assoc"},{"key":"748_CR75","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bcp.12230","volume":"77","author":"D Trenk","year":"2014","unstructured":"Trenk D, Hochholzer W. Genetics of platelet inhibitor treatment. Br J Clin Pharmacol 2014; 77: 642-53.","journal-title":"Br J Clin Pharmacol"},{"key":"748_CR76","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jjcc.2014.07.016","volume":"65","author":"Y Arima","year":"2015","unstructured":"Arima Y, Hokimoto S, Akasaka T, et al. Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina. J Cardiol 2015; 65: 494-500.","journal-title":"J Cardiol"},{"key":"748_CR77","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/MJT.0000000000000125","volume":"22","author":"EZ Golukhova","year":"2015","unstructured":"Golukhova EZ, Ryabinina MN, Bulaeva NI, Grigorian MV, Kubova M, Serebruany VL. Clopidogrel response variability: impact of genetic polymorphism and platelet biomarkers for predicting adverse outcomes poststenting. Am J Ther 2015; 22: 222-30.","journal-title":"Am J Ther"},{"key":"748_CR78","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1001\/jama.2011.1880","volume":"306","author":"MV Holmes","year":"2011","unstructured":"Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 2011; 306: 2704-14.","journal-title":"JAMA"},{"key":"748_CR79","doi-asserted-by":"crossref","first-page":"d4588","DOI":"10.1136\/bmj.d4588","volume":"343","author":"T Bauer","year":"2011","unstructured":"Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 2011; 343: d4588.","journal-title":"BMJ"},{"key":"748_CR80","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.thromres.2014.12.007","volume":"135","author":"L Zhang","year":"2015","unstructured":"Zhang L, Yang J, Zhu X, et al. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis. Thromb Res 2015; 135: 449-58.","journal-title":"Thromb Res"},{"key":"748_CR81","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijcard.2015.03.171","volume":"186","author":"J Samardzic","year":"2015","unstructured":"Samardzic J, Bozina N, Skoric B, et al. CYP2C19*2 genotype influence in acute coronary syndrome patients undergoing serial clopidogrel dose tailoring based on platelet function testing: analysis from randomized controlled trial NCT02096419. Int J Cardiol 2015; 186: 282-5.","journal-title":"Int J Cardiol"},{"key":"748_CR82","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2217\/pgs.14.180","volume":"16","author":"JA Lee","year":"2015","unstructured":"Lee JA, Lee CR, Reed BN, et al. Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. Pharmacogenomics 2015; 16: 303-13.","journal-title":"Pharmacogenomics"},{"key":"748_CR83","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00210-003-0832-2","volume":"369","author":"UM Zanger","year":"2004","unstructured":"Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 23-37.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"748_CR84","doi-asserted-by":"crossref","first-page":"368979","DOI":"10.1155\/2015\/368979","volume":"2015","author":"E Yiannakopoulou","year":"2015","unstructured":"Yiannakopoulou E. Pharmacogenomics and opioid analgesics: clinical implications. Int J Genomics 2015; 2015: 368979.","journal-title":"Int J Genomics"},{"key":"748_CR85","first-page":"284","volume":"60","author":"C Sachse","year":"1997","unstructured":"Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60: 284-95.","journal-title":"Am J Hum Genet"},{"key":"748_CR86","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/clpt.2013.254","volume":"95","author":"KR Crews","year":"2014","unstructured":"Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther 2014; 95: 376-82.","journal-title":"Clin Pharmacol Ther"},{"key":"748_CR87","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1177\/106002809703101114","volume":"31","author":"EJ Frackiewicz","year":"1997","unstructured":"Frackiewicz EJ, Sramek JJ, Herrera JM, Kurtz NM, Cutler NR. Ethnicity and antipsychotic response. Ann Pharmacother 1997; 31: 1360-9.","journal-title":"Ann Pharmacother"},{"key":"748_CR88","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0140-6736(06)69255-6","volume":"368","author":"G Koren","year":"2006","unstructured":"Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006; 368: 704.","journal-title":"Lancet"},{"key":"748_CR89","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0304-3959(98)00021-9","volume":"76","author":"K Eckhardt","year":"1998","unstructured":"Eckhardt K, Li S, Ammon S, Schanzle G, Mikus G, Eichelbaum M. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 1998; 76: 27-33.","journal-title":"Pain"},{"key":"748_CR90","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00000542-200503000-00011","volume":"102","author":"KA Candiotti","year":"2005","unstructured":"Candiotti KA, Birnbach DJ, Lubarsky DA, et al. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? Anesthesiology 2005; 102: 543-9.","journal-title":"Anesthesiology"},{"key":"748_CR91","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1213\/01.ane.0000200364.55798.3f","volume":"102","author":"PK Janicki","year":"2006","unstructured":"Janicki PK, Schuler HG, Jarzembowski TM, Rossi M 2nd. Prevention of postoperative nausea and vomiting with granisetron and dolasetron in relation to CYP2D6 genotype. Anesth Analg 2006; 102: 1127-33.","journal-title":"Anesth Analg"},{"key":"748_CR92","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/1389200217666151105125425","volume":"17","author":"A Lymperopoulos","year":"2015","unstructured":"Lymperopoulos A, McCrink KA, Brill A. Impact of CYP2D6 genetic variation on the response of the cardiovascular patient to carvedilol and metoprolol. Curr Drug Metab 2015; 17: 30-6.","journal-title":"Curr Drug Metab"},{"key":"748_CR93","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1006\/bbrc.2001.4505","volume":"281","author":"A Westlind","year":"2001","unstructured":"Westlind A, Malmebo S, Johansson I, et al. Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 2001; 281: 1349-55.","journal-title":"Biochem Biophys Res Commun"},{"key":"748_CR94","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/sj.clpt.6100237","volume":"82","author":"ED Kharasch","year":"2007","unstructured":"Kharasch ED, Walker A, Isoherranen N, et al. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther 2007; 82: 410-26.","journal-title":"Clin Pharmacol Ther"},{"key":"748_CR95","first-page":"1072","volume":"25","author":"RB Labroo","year":"1997","unstructured":"Labroo RB, Paine MF, Thummel KE, Kharasch ED. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos 1997; 25: 1072-80.","journal-title":"Drug Metab Dispos"},{"key":"748_CR96","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1016\/0006-2952(88)90622-3","volume":"37","author":"G Fabre","year":"1988","unstructured":"Fabre G, Rahmani R, Placidi M, et al. Characterization of midazolam metabolism using human hepatic microsomal fractions and hepatocytes in suspension obtained by perfusing whole human livers. Biochem Pharmacol 1988; 37: 4389-97.","journal-title":"Biochem Pharmacol"},{"key":"748_CR97","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/clpt.1988.31","volume":"43","author":"H Oldenhof","year":"1988","unstructured":"Oldenhof H, de Jong M, Steenhoek A, Janknegt R. Clinical pharmacokinetics of midazolam in intensive care patients, a wide interpatient variability? Clin Pharmacol Ther 1988; 43: 263-9.","journal-title":"Clin Pharmacol Ther"},{"key":"748_CR98","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/mol.62.1.162","volume":"62","author":"YS Lin","year":"2002","unstructured":"Lin YS, Dowling AL, Quigley SD, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002; 62: 162-72.","journal-title":"Mol Pharmacol"},{"key":"748_CR99","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1067\/mcp.2000.108506","volume":"68","author":"C Wandel","year":"2000","unstructured":"Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5\u2019-promoter region polymorphism. Clin Pharmacol Ther 2000; 68: 82-91.","journal-title":"Clin Pharmacol Ther"},{"key":"748_CR100","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1124\/dmd.105.003822","volume":"33","author":"JN Roy","year":"2005","unstructured":"Roy JN, Lajoie J, Zijenah LS, et al. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos 2005; 33: 884-7.","journal-title":"Drug Metab Dispos"},{"key":"748_CR101","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/CCM.0b013e318275d014","volume":"41","author":"Y Skrobik","year":"2013","unstructured":"Skrobik Y, Leger C, Cossette M, Michaud V, Turgeon J. Factors predisposing to coma and delirium: fentanyl and midazolam exposure; CYP3A5, ABCB1, and ABCG2 genetic polymorphisms; and inflammatory factors. Crit Care Med 2013; 41: 999-1008.","journal-title":"Crit Care Med"},{"key":"748_CR102","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.cca.2010.12.038","volume":"412","author":"R Yuan","year":"2011","unstructured":"Yuan R, Zhang X, Deng Q, Wu Y, Xiang G. Impact of CYP3A4*1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. Clin Chim Acta 2011; 412: 755-60.","journal-title":"Clin Chim Acta"},{"key":"748_CR103","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/sj.clpt.6100046","volume":"81","author":"HJ Park","year":"2007","unstructured":"Park HJ, Shinn HK, Ryu SH, Lee HS, Park CS, Kang JH. Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. Clin Pharmacol Ther 2007; 81: 539-46.","journal-title":"Clin Pharmacol Ther"},{"key":"748_CR104","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0009-9236(03)00168-1","volume":"74","author":"DA Hesselink","year":"2003","unstructured":"Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-54.","journal-title":"Clin Pharmacol Ther"},{"key":"748_CR105","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1124\/dmd.105.008680","volume":"34","author":"Y Dai","year":"2006","unstructured":"Dai Y, Hebert MF, Isoherranen N, et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 2006; 34: 836-47.","journal-title":"Drug Metab Dispos"},{"key":"748_CR106","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1164\/rccm.201306-1150OC","volume":"189","author":"VJ Page","year":"2014","unstructured":"Page VJ, Davis D, Zhao XB, et al. Statin use and risk of delirium in the critically ill. Am J Respir Crit Care Med 2014; 189: 666-73.","journal-title":"Am J Respir Crit Care Med"},{"key":"748_CR107","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1053\/j.jvca.2012.09.013","volume":"27","author":"R Hall","year":"2013","unstructured":"Hall R. Identification of inflammatory mediators and their modulation by strategies for the management of the systemic inflammatory response during cardiac surgery. J Cardiothorac Vasc Anesth 2013; 27: 983-1033.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"748_CR108","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/01.fpc.0000114762.78957.a5","volume":"14","author":"KT Kivisto","year":"2004","unstructured":"Kivisto KT, Niemi M, Schaeffeler E, et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 2004; 14: 523-5.","journal-title":"Pharmacogenetics"},{"key":"748_CR109","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00280-009-1029-2","volume":"65","author":"K Fujita","year":"2010","unstructured":"Fujita K, Ando Y, Yamamoto W, et al. Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer. Cancer Chemother Pharmacol 2010; 65: 251-8.","journal-title":"Cancer Chemother Pharmacol"},{"key":"748_CR110","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/ajh.21051","volume":"83","author":"DS Darbari","year":"2008","unstructured":"Darbari DS, van Schaik RH, Capparelli EV, Rana S, McCarter R, van den Anker J. UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am J Hematol 2008; 83: 200-2.","journal-title":"Am J Hematol"},{"key":"748_CR111","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1034\/j.1399-6576.2003.00077.x","volume":"47","author":"G Niemi","year":"2003","unstructured":"Niemi G, Breivik H. The minimally effective concentration of adrenaline in a low-concentration thoracic epidural analgesic infusion of bupivacaine, fentanyl and adrenaline after major surgery. A randomized, double-blind, dose-finding study. Acta Anaesthesiol Scand 2003; 47: 439-50.","journal-title":"Acta Anaesthesiol Scand"},{"key":"748_CR112","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pain.2005.03.032","volume":"116","author":"TT Rakvag","year":"2005","unstructured":"Rakvag TT, Klepstad P, Baar C, et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 2005; 116: 73-8.","journal-title":"Pain"},{"key":"748_CR113","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/FPC.0000000000000170","volume":"25","author":"ML Alvarellos","year":"2015","unstructured":"Alvarellos ML, McDonagh EM, Patel S, McLeod HL, Altman RB, Klein TE. PharmGKB summary: succinylcholine pathway, pharmacokinetics\/pharmacodynamics. Pharmacogenet Genomics 2015; 25: 622-30.","journal-title":"Pharmacogenet Genomics"},{"key":"748_CR114","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1213\/00000539-199311000-00028","volume":"77","author":"PS Glass","year":"1993","unstructured":"Glass PS, Hardman D, Kamiyama Y, et al. Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B). Anesth Analg 1993; 77: 1031-40.","journal-title":"Anesth Analg"},{"key":"748_CR115","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/00000542-200503000-00009","volume":"102","author":"S Levano","year":"2005","unstructured":"Levano S, Ginz H, Siegemund M, et al. Genotyping the butyrylcholinesterase in patients with prolonged neuromuscular block after succinylcholine. Anesthesiology 2005; 102: 531-5.","journal-title":"Anesthesiology"},{"key":"748_CR116","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00008571-200104000-00004","volume":"11","author":"AJ Fretland","year":"2001","unstructured":"Fretland AJ, Leff MA, Doll MA, Hein DW. Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics 2001; 11: 207-15.","journal-title":"Pharmacogenetics"},{"key":"748_CR117","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1136\/bmj.284.6320.936","volume":"284","author":"R Mansilla-Tinoco","year":"1982","unstructured":"Mansilla-Tinoco R, Harland SJ, Ryan PJ, et al. Hydralazine, antinuclear antibodies, and the lupus syndrome. Br Med J (Clin Res Ed) 1982; 284: 936-9.","journal-title":"Br Med J (Clin Res Ed)"},{"key":"748_CR118","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/FPC.0b013e3283385a1c","volume":"21","author":"LM Hodges","year":"2011","unstructured":"Hodges LM, Markova SM, Chinn LW, et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics 2011; 21: 152-61.","journal-title":"Pharmacogenet Genomics"},{"key":"748_CR119","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/gm187","volume":"2","author":"PJ Jannetto","year":"2010","unstructured":"Jannetto PJ, Bratanow NC. Pharmacogenomic considerations in the opioid management of pain. Genome Med 2010; 2: 66.","journal-title":"Genome Med"},{"key":"748_CR120","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/sj.clpt.6100385","volume":"83","author":"D Campa","year":"2008","unstructured":"Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1\/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008; 83: 559-66.","journal-title":"Clin Pharmacol Ther"},{"key":"748_CR121","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00228-003-0567-5","volume":"58","author":"C Verstuyft","year":"2003","unstructured":"Verstuyft C, Schwab M, Schaeffeler E, et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 2003; 58: 809-12.","journal-title":"Eur J Clin Pharmacol"},{"key":"748_CR122","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000442712","volume":"97","author":"D Stokanovic","year":"2016","unstructured":"Stokanovic D, Nikolic VN, Konstantinovic SS, et al. P-glycoprotein polymorphism C3435T is associated with dose-adjusted clopidogrel and 2-Oxo-clopidogrel concentration. Pharmacology 2016; 97: 101-6.","journal-title":"Pharmacology"},{"key":"748_CR123","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.thromres.2015.08.025","volume":"136","author":"B Calderon-Cruz","year":"2015","unstructured":"Calderon-Cruz B, Rodriguez-Galvan K, Manzo-Francisco LA, et al. C3435T polymorphism of the ABCB1 gene is associated with poor clopidogrel responsiveness in a Mexican population undergoing percutaneous coronary intervention. Thromb Res 2015; 136: 894-8.","journal-title":"Thromb Res"},{"key":"748_CR124","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.gene.2014.12.051","volume":"558","author":"XQ Wang","year":"2015","unstructured":"Wang XQ, Shen CL, Wang BN, Huang XH, Hu ZL, Li J. Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome. Gene 2015; 558: 200-7.","journal-title":"Gene"},{"key":"748_CR125","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jacc.2011.08.061","volume":"59","author":"B Parvez","year":"2012","unstructured":"Parvez B, Chopra N, Rowan S, et al. A common beta1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. J Am Coll Cardiol 2012; 59: 49-56.","journal-title":"J Am Coll Cardiol"},{"key":"748_CR126","doi-asserted-by":"crossref","first-page":"e0129305","DOI":"10.1371\/journal.pone.0129305","volume":"10","author":"T Avni","year":"2015","unstructured":"Avni T, Lador A, Lev S, Leibovici L, Paul M, Grossman A. Vasopressors for the treatment of septic shock: systematic review and meta-analysis. PloS One 2015; 10: e0129305.","journal-title":"PloS One"},{"key":"748_CR127","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000053705","volume":"124","author":"E Israel","year":"2001","unstructured":"Israel E, Drazen JM, Liggett SB, et al. Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma. Int Arch Allergy Immunol 2001; 124: 183-6.","journal-title":"Int Arch Allergy Immunol"},{"key":"748_CR128","doi-asserted-by":"crossref","first-page":"S197","DOI":"10.1164\/ajrccm.161.supplement_2.a1q4-10","volume":"161","author":"SB Liggett","year":"2000","unstructured":"Liggett SB. Beta(2)-adrenergic receptor pharmacogenetics. Am J Respir Crit Care Med 2000; 161: S197-201.","journal-title":"Am J Respir Crit Care Med"},{"key":"748_CR129","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/00000542-200604000-00006","volume":"104","author":"RM Smiley","year":"2006","unstructured":"Smiley RM, Blouin JL, Negron M, Landau R. beta2-adrenoceptor genotype affects vasopressor requirements during spinal anesthesia for cesarean delivery. Anesthesiology 2006; 104: 644-50.","journal-title":"Anesthesiology"},{"key":"748_CR130","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/00000542-199809000-00008","volume":"89","author":"JV Booth","year":"1998","unstructured":"Booth JV, Landolfo KP, Chesnut LC, et al. Acute depression of myocardial beta-adrenergic receptor signaling during cardiopulmonary bypass: impairment of the adenylyl cyclase moiety. Duke Heart Center Perioperative Desensitization Group. Anesthesiology 1998; 89: 602-11.","journal-title":"Anesthesiology"},{"key":"748_CR131","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/clpt.2010.315","volume":"89","author":"JA Johnson","year":"2011","unstructured":"Johnson JA, Liggett SB. Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions. Clin Pharmacol Ther 2011; 89: 366-78.","journal-title":"Clin Pharmacol Ther"},{"key":"748_CR132","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0009-9236(03)00224-8","volume":"74","author":"J Liu","year":"2003","unstructured":"Liu J, Liu ZQ, Tan ZR, et al. Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther 2003; 74: 372-9.","journal-title":"Clin Pharmacol Ther"},{"key":"748_CR133","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0009-9236(02)17734-4","volume":"73","author":"GG Sofowora","year":"2003","unstructured":"Sofowora GG, Dishy V, Muszkat M, et al. A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther 2003; 73: 366-71.","journal-title":"Clin Pharmacol Ther"},{"key":"748_CR134","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/CCM.0b013e3182783b72","volume":"41","author":"J Barr","year":"2013","unstructured":"Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med 2013; 41: 263-306.","journal-title":"Crit Care Med"},{"key":"748_CR135","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1176\/appi.ajp.2009.09040598","volume":"167","author":"JP Zhang","year":"2010","unstructured":"Zhang JP, Lencz T, Malhotra AK. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 2010; 167: 763-72.","journal-title":"Am J Psychiatry"},{"key":"748_CR136","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/070674371405900203","volume":"59","author":"EJ Brandl","year":"2014","unstructured":"Brandl EJ, Kennedy JL, Muller DJ. Pharmacogenetics of antipsychotics. Can J Psychiatry 2014; 59: 76-88.","journal-title":"Can J Psychiatry"},{"key":"748_CR137","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1176\/appi.ajp.158.5.802","volume":"158","author":"M Schafer","year":"2001","unstructured":"Schafer M, Rujescu D, Giegling I, et al. Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J Psychiatry 2001; 158: 802-4.","journal-title":"Am J Psychiatry"},{"key":"748_CR138","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00000542-200608000-00016","volume":"105","author":"WY Chou","year":"2006","unstructured":"Chou WY, Wang CH, Liu PH, Liu CC, Tseng CC, Jawan B. Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology 2006; 105: 334-7.","journal-title":"Anesthesiology"},{"key":"748_CR139","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/ALN.0b013e318182af21","volume":"109","author":"AT Sia","year":"2008","unstructured":"Sia AT, Lim Y, Lim EC, et al. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 2008; 109: 520-6.","journal-title":"Anesthesiology"},{"key":"748_CR140","first-page":"33","volume":"77","author":"W Zhang","year":"2011","unstructured":"Zhang W, Yuan JJ, Kan QC, Zhang LR, Chang YZ, Wang ZY. Study of the OPRM1 A118G genetic polymorphism associated with postoperative nausea and vomiting induced by fentanyl intravenous analgesia. Minerva Anestesiol 2011; 77: 33-9.","journal-title":"Minerva Anestesiol"},{"issue":"Suppl 10","key":"748_CR141","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1097\/AJP.0b013e3181c49e11","volume":"26","author":"CE Argoff","year":"2010","unstructured":"Argoff CE. Clinical implications of opioid pharmacogenetics. Clin J Pain 2010; 26(Suppl 10): S16-20.","journal-title":"Clin J Pain"},{"key":"748_CR142","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.tips.2010.04.002","volume":"31","author":"J Lotsch","year":"2010","unstructured":"Lotsch J, Geisslinger G. A critical appraisal of human genotyping for pain therapy. Trends Pharmacol Sci 2010; 31: 312-7.","journal-title":"Trends Pharmacol Sci"},{"key":"748_CR143","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/cc7702","volume":"13","author":"AM Sutherland","year":"2009","unstructured":"Sutherland AM, Walley KR. Bench-to-bedside review: association of genetic variation with sepsis. Crit Care 2009; 13: 210.","journal-title":"Crit Care"},{"issue":"Suppl 1","key":"748_CR144","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1007\/s001340051125","volume":"26","author":"SJ Deventer van","year":"2000","unstructured":"van Deventer SJ. Cytokine and cytokine receptor polymorphisms in infectious disease. Intensive Care Med 2000; 26(Suppl 1): S98-102.","journal-title":"Intensive Care Med"},{"key":"748_CR145","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.molmed.2014.01.007","volume":"20","author":"JC Marshall","year":"2014","unstructured":"Marshall JC. Why have clinical trials in sepsis failed? Trends Mol Med 2014; 20: 195-203.","journal-title":"Trends Mol Med"},{"key":"748_CR146","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(15)70112-X","volume":"15","author":"J Cohen","year":"2015","unstructured":"Cohen J, Vincent JL, Adhikari NK, et al. Sepsis: a roadmap for future research. Lancet Infect Dis 2015; 15: 581-614.","journal-title":"Lancet Infect Dis"},{"key":"748_CR147","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/MAJ.0000000000000558","volume":"350","author":"F Pinheiro da Silva","year":"2015","unstructured":"Pinheiro da Silva F, Cesar Machado MC. Personalized medicine for sepsis. Am J Med Sci 2015; 350: 409-13.","journal-title":"Am J Med Sci"},{"key":"748_CR148","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ccc.2010.12.012","volume":"27","author":"SP LaRosa","year":"2011","unstructured":"LaRosa SP, Opal SM. Biomarkers: the future. Crit Care Clin 2011; 27: 407-19.","journal-title":"Crit Care Clin"},{"key":"748_CR149","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S2213-2600(16)00046-1","volume":"4","author":"EE Davenport","year":"2016","unstructured":"Davenport EE, Burnham KL, Radhakrishnan J, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med 2016; 4: 259-71.","journal-title":"Lancet Respir Med"},{"key":"748_CR150","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJM200008033430506","volume":"343","author":"R Medzhitov","year":"2000","unstructured":"Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med 2000; 343: 338-44.","journal-title":"N Engl J Med"},{"key":"748_CR151","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(98)08350-0","volume":"353","author":"ML Hibberd","year":"1999","unstructured":"Hibberd ML, Sumiya M, Summerfield JA, Booy R, Levin M, Meningococcal Research Group. Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Lancet 1999; 353: 1049-53.","journal-title":"Lancet"},{"key":"748_CR152","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/313588","volume":"30","author":"AM Yee","year":"2000","unstructured":"Yee AM, Phan HM, Zuniga R, Salmon JE, Musher DM. Association between FcgammaRIIa-R131 allotype and bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30: 25-8.","journal-title":"Clin Infect Dis"},{"key":"748_CR153","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/00003246-200205000-00003","volume":"30","author":"S Gibot","year":"2002","unstructured":"Gibot S, Cariou A, Drouet L, Rossignol M, Ripoll L. Association between a genomic polymorphism within the CD14 locus and septic shock susceptibility and mortality rate. Crit Care Med 2002; 30: 969-73.","journal-title":"Crit Care Med"},{"key":"748_CR154","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0140-6736(99)02220-5","volume":"354","author":"PW Hermans","year":"1999","unstructured":"Hermans PW, Hibberd ML, Booy R, et al. 4G\/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Lancet 1999; 354: 556-60.","journal-title":"Lancet"},{"key":"748_CR155","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13054-016-1330-5","volume":"20","author":"A Sapru","year":"2016","unstructured":"Sapru A, Liu KD, Wiemels J, et al. Association of common genetic variation in the protein C pathway genes with clinical outcomes in acute respiratory distress syndrome. Crit Care 2016; 20: 151.","journal-title":"Crit Care"},{"key":"748_CR156","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.imlet.2006.04.010","volume":"106","author":"A Pachot","year":"2006","unstructured":"Pachot A, Lepape A, Vey S, Bienvenu J, Mougin B, Monneret G. Systemic transcriptional analysis in survivor and non-survivor septic shock patients: a preliminary study. Immunol Lett 2006; 106: 63-71.","journal-title":"Immunol Lett"},{"key":"748_CR157","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1164\/rccm.200803-462OC","volume":"178","author":"MM Wurfel","year":"2008","unstructured":"Wurfel MM, Gordon AC, Holden TD, et al. Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis. Am J Respir Crit Care Med 2008; 178: 710-20.","journal-title":"Am J Respir Crit Care Med"},{"key":"748_CR158","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/archinte.162.9.1028","volume":"162","author":"E Lorenz","year":"2002","unstructured":"Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002; 162: 1028-32.","journal-title":"Arch Intern Med"},{"key":"748_CR159","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1186\/s13054-015-1130-3","volume":"19","author":"JW Gao","year":"2015","unstructured":"Gao JW, Zhang AQ, Wang X, et al. Association between the TLR2 Arg753Gln polymorphism and the risk of sepsis: a meta-analysis. Crit Care 2015; 19: 416.","journal-title":"Crit Care"},{"key":"748_CR160","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1096\/fj.09-129445","volume":"23","author":"S Yende","year":"2009","unstructured":"Yende S, Angus DC, Kong L, et al. The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community-acquired pneumonia. FASEB J 2009; 23: 2403-11.","journal-title":"FASEB J"},{"key":"748_CR161","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1007\/s00134-007-0860-3","volume":"33","author":"J Michalek","year":"2007","unstructured":"Michalek J, Svetlikova P, Fedora M, et al. Bactericidal permeability increasing protein gene variants in children with sepsis. Intensive Care Med 2007; 33: 2158-64.","journal-title":"Intensive Care Med"},{"key":"748_CR162","doi-asserted-by":"crossref","first-page":"e54883","DOI":"10.1371\/journal.pone.0054883","volume":"8","author":"L Li","year":"2013","unstructured":"Li L, Nie W, Zhou H, Yuan W, Li W, Huang W. Association between plasminogen activator inhibitor-1-675 4G\/5G polymorphism and sepsis: a meta-analysis. PloS One 2013; 8: e54883.","journal-title":"PloS One"},{"key":"748_CR163","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/cge.12368","volume":"86","author":"E Christaki","year":"2014","unstructured":"Christaki E, Giamarellos-Bourboulis EJ. The beginning of personalized medicine in sepsis: small steps to a bright future. Clin Genet 2014; 86: 56-61.","journal-title":"Clin Genet"},{"key":"748_CR164","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cyto.2012.06.016","volume":"60","author":"E Watanabe","year":"2012","unstructured":"Watanabe E, Zehnbauer BA, Oda S, Sato Y, Hirasawa H, Buchman TG. Tumor necrosis factor-308 polymorphism (rs1800629) is associated with mortality and ventilator duration in 1057 Caucasian patients. Cytokine 2012; 60: 249-56.","journal-title":"Cytokine"},{"key":"748_CR165","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/jama.282.6.561","volume":"282","author":"JP Mira","year":"1999","unstructured":"Mira JP, Cariou A, Grall F, et al. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 1999; 282: 561-8.","journal-title":"JAMA"},{"key":"748_CR166","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1164\/rccm.200612-1819OC","volume":"176","author":"BM Tang","year":"2007","unstructured":"Tang BM, McLean AS, Dawes IW, Huang SJ, Lin RC. The use of gene-expression profiling to identify candidate genes in human sepsis. Am J Respir Crit Care Med 2007; 176: 676-84.","journal-title":"Am J Respir Crit Care Med"},{"key":"748_CR167","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/CCM.0b013e31819b52fd","volume":"37","author":"BM Tang","year":"2009","unstructured":"Tang BM, McLean AS, Dawes IW, Huang SJ, Lin RC. Gene-expression profiling of peripheral blood mononuclear cells in sepsis. Crit Care Med 2009; 37: 882-8.","journal-title":"Crit Care Med"},{"key":"748_CR168","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1097\/CCM.0000000000000325","volume":"42","author":"SM Opal","year":"2014","unstructured":"Opal SM, Dellinger RP, Vincent JL, Masur H, Angus DC. The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C? Crit Care Med 2014; 42: 1714-21.","journal-title":"Crit Care Med"},{"key":"748_CR169","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/jama.2016.0289","volume":"315","author":"M Shankar-Hari","year":"2016","unstructured":"Shankar-Hari M, Phillips GS, Levy ML, et al. Developing a New definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315: 775-87.","journal-title":"JAMA"},{"key":"748_CR170","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1097\/CCM.0b013e318246b546","volume":"40","author":"HR Wong","year":"2012","unstructured":"Wong HR. Genetics and genomics in pediatric septic shock. Crit Care Med 2012; 40: 1618-26.","journal-title":"Crit Care Med"},{"key":"748_CR171","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1542\/peds.2009-3274","volume":"125","author":"TT Cornell","year":"2010","unstructured":"Cornell TT, Wynn J, Shanley TP, Wheeler DS, Wong HR. Mechanisms and regulation of the gene-expression response to sepsis. Pediatrics 2010; 125: 1248-58.","journal-title":"Pediatrics"},{"key":"748_CR172","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1097\/01.CCM.0000145951.76082.77","volume":"32","author":"PV Sackey","year":"2004","unstructured":"Sackey PV, Martling CR, Granath F, Radell PJ. Prolonged isoflurane sedation of intensive care unit patients with the Anesthetic Conserving Device. Crit Care Med 2004; 32: 2241-6.","journal-title":"Crit Care Med"},{"key":"748_CR173","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/bja\/aev225","volume":"115","author":"PM Hopkins","year":"2015","unstructured":"Hopkins PM, Ruffert H, Snoeck MM, et al. European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. Br J Anaesth 2015; 115: 531-9.","journal-title":"Br J Anaesth"},{"key":"748_CR174","first-page":"355","volume":"10","author":"D Schneiderbanger","year":"2014","unstructured":"Schneiderbanger D, Johannsen S, Roewer N, Schuster F. Management of malignant hyperthermia: diagnosis and treatment. Ther Clin Risk Manag 2014; 10: 355-62.","journal-title":"Ther Clin Risk Manag"},{"key":"748_CR175","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/978-3-642-00663-0_17","volume":"196","author":"M Pirmohamed","year":"2010","unstructured":"Pirmohamed M. Pharmacogenetics of idiosyncratic adverse drug reactions. Handb Exp Pharmacol 2010; 196: 477-91.","journal-title":"Handb Exp Pharmacol"},{"key":"748_CR176","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2217\/pgs.14.65","volume":"15","author":"KM Bloch","year":"2014","unstructured":"Bloch KM, Sills GJ, Pirmohamed M, Alfirevic A. Pharmacogenetics of antiepileptic drug-induced hypersensitivity. Pharmacogenomics 2014; 15: 857-68.","journal-title":"Pharmacogenomics"},{"key":"748_CR177","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/FPC.0000000000000021","volume":"24","author":"S Grover","year":"2014","unstructured":"Grover S, Kukreti R. HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis. Pharmacogenet Genomics 2014; 24: 94-112.","journal-title":"Pharmacogenet Genomics"},{"key":"748_CR178","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.2217\/pgs.15.128","volume":"16","author":"S Rufini","year":"2015","unstructured":"Rufini S, Ciccacci C, Politi C, Giardina E, Novelli G, Borgiani P. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update on pharmacogenetics studies in drug-induced severe skin reaction. Pharmacogenomics 2015; 16: 1989-2002.","journal-title":"Pharmacogenomics"},{"key":"748_CR179","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3181\/0806-S-195","volume":"233","author":"M Patnaik","year":"2008","unstructured":"Patnaik M, Renda MJ, Athanasiou MC, Reed CR. The role of pharmacogenetics in treating central nervous system disorders. Exp Biol Med (Maywood) 2008; 233: 1504-9.","journal-title":"Exp Biol Med (Maywood)"},{"key":"748_CR180","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/clpt.2013.103","volume":"94","author":"SG Leckband","year":"2013","unstructured":"Leckband SG, Kelsoe JR, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther 2013; 94: 324-8.","journal-title":"Clin Pharmacol Ther"},{"key":"748_CR181","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/01.COH.0000221600.64659.d3","volume":"1","author":"EJ Phillips","year":"2006","unstructured":"Phillips EJ. The pharmacogenetics of antiretroviral therapy. Curr Opin HIV AIDS 2006; 1: 249-56.","journal-title":"Curr Opin HIV AIDS"},{"key":"748_CR182","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","volume":"359","author":"S Mallal","year":"2002","unstructured":"Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727-32.","journal-title":"Lancet"},{"key":"748_CR183","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1073\/pnas.0307067101","volume":"101","author":"AM Martin","year":"2004","unstructured":"Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004; 101: 4180-5.","journal-title":"Proc Natl Acad Sci USA"},{"key":"748_CR184","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","volume":"358","author":"S Mallal","year":"2008","unstructured":"Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-79.","journal-title":"N Engl J Med"},{"key":"748_CR185","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00002030-200501030-00014","volume":"19","author":"AM Martin","year":"2005","unstructured":"Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 2005; 19: 97-9.","journal-title":"AIDS"},{"key":"748_CR186","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/amiajnl-2013-001873","volume":"21","author":"BR Goldspiel","year":"2014","unstructured":"Goldspiel BR, Flegel WA, DiPatrizio G, et al. Integrating pharmacogenetic information and clinical decision support into the electronic health record. J Am Med Inform Assoc 2014; 21: 522-8.","journal-title":"J Am Med Inform Assoc"},{"key":"748_CR187","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2012.12.061","volume":"517","author":"H Abriel","year":"2013","unstructured":"Abriel H, Zaklyazminskaya EV. Cardiac channelopathies: genetic and molecular mechanisms. Gene 2013; 517: 1-11.","journal-title":"Gene"},{"key":"748_CR188","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jacc.2013.04.044","volume":"62","author":"PJ Schwartz","year":"2013","unstructured":"Schwartz PJ, Ackerman MJ, George AL Jr, Wilde AA. Impact of genetics on the clinical management of channelopathies. J Am Coll Cardiol 2013; 62: 169-80.","journal-title":"J Am Coll Cardiol"},{"key":"748_CR189","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5339\/gcsp.2015.26","volume":"2015","author":"S Baskar","year":"2015","unstructured":"Baskar S, Aziz PF. Genotype-phenotype correlation in long QT syndrome. Glob Cardiol Sci Pract 2015; 2015: 26.","journal-title":"Glob Cardiol Sci Pract"},{"key":"748_CR190","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/S0140-6736(12)61413-5","volume":"380","author":"RM John","year":"2012","unstructured":"John RM, Tedrow UB, Koplan BA, et al. Ventricular arrhythmias and sudden cardiac death. Lancet 2012; 380: 1520-9.","journal-title":"Lancet"},{"key":"748_CR191","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pharmthera.2008.02.001","volume":"118","author":"C Patel","year":"2008","unstructured":"Patel C, Antzelevitch C. Pharmacological approach to the treatment of long and short QT syndromes. Pharmacol Ther 2008; 118: 138-51.","journal-title":"Pharmacol Ther"},{"key":"748_CR192","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0002-9343(01)01011-7","volume":"112","author":"IA Khan","year":"2002","unstructured":"Khan IA. Clinical and therapeutic aspects of congenital and acquired long QT syndrome. Am J Med 2002; 112: 58-66.","journal-title":"Am J Med"},{"key":"748_CR193","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1399-0004.2011.01746.x","volume":"81","author":"EA Varga","year":"2012","unstructured":"Varga EA, Kujovich JL. Management of inherited thrombophilia: guide for genetics professionals. Clin Genet 2012; 81: 7-17.","journal-title":"Clin Genet"},{"issue":"1801-12","key":"748_CR194","first-page":"e7","volume":"12","author":"X Qi","year":"2014","unstructured":"Qi X, Ren W, De Stefano V, Fan D. Associations of coagulation factor V Leiden and prothrombin G20210A mutations with Budd-Chiari syndrome and portal vein thrombosis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014; 12(1801-12): e7.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"748_CR195","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1002\/ajh.23128","volume":"87","author":"JA Heit","year":"2012","unstructured":"Heit JA. Predicting the risk of venous thromboembolism recurrence. Am J Hematol 2012; 87(Suppl 1): S63-7.","journal-title":"Am J Hematol"},{"key":"748_CR196","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(94)92939-4","volume":"343","author":"J Voorberg","year":"1994","unstructured":"Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet 1994; 343: 1535-6.","journal-title":"Lancet"},{"key":"748_CR197","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood.V88.10.3698.bloodjournal88103698","volume":"88","author":"SR Poort","year":"1996","unstructured":"Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3\u2019-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.","journal-title":"Blood"},{"key":"748_CR198","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11239-013-1005-x","volume":"37","author":"T Yin","year":"2014","unstructured":"Yin T, Miyata T. Dysfunction of protein C anticoagulant system, main genetic risk factor for venous thromboembolism in Northeast Asians. J Thromb Thrombolysis 2014; 37: 56-65.","journal-title":"J Thromb Thrombolysis"},{"key":"748_CR199","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/jth.12678","volume":"12","author":"RE Roach","year":"2014","unstructured":"Roach RE, Cannegieter SC, Lijfering WM. Differential risks in men and women for first and recurrent venous thrombosis: the role of genes and environment. J Thromb Haemost 2014; 12: 1593-600.","journal-title":"J Thromb Haemost"},{"key":"748_CR200","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/humupd\/dmt028","volume":"19","author":"ESHRE Capri Workshop Group","year":"2013","unstructured":"ESHRE Capri Workshop Group. Venous thromboembolism in women: a specific reproductive health risk. Hum Reprod Update 2013; 19: 471-82.","journal-title":"Hum Reprod Update"},{"key":"748_CR201","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.blre.2014.03.005","volume":"28","author":"SM Bleker","year":"2014","unstructured":"Bleker SM, Coppens M, Middeldorp S. Sex, thrombosis and inherited thrombophilia. Blood Rev 2014; 28: 123-33.","journal-title":"Blood Rev"},{"issue":"2 Suppl","key":"748_CR202","doi-asserted-by":"crossref","first-page":"e195S","DOI":"10.1378\/chest.11-2296","volume":"141","author":"SR Kahn","year":"2012","unstructured":"Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): e195S-226S.","journal-title":"Chest"},{"key":"748_CR203","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1160\/TH13-01-0011","volume":"110","author":"V Stefano De","year":"2013","unstructured":"De Stefano V, Rossi E. Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the Guidelines from Scientific Societies and Working Groups. Thromb Haemost 2013; 110: 697-705.","journal-title":"Thromb Haemost"},{"key":"748_CR204","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tcm.2014.09.001","volume":"25","author":"JA Johnson","year":"2015","unstructured":"Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med 2015; 25: 33-41.","journal-title":"Trends Cardiovasc Med"},{"key":"748_CR205","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1016\/j.ijcard.2013.07.151","volume":"168","author":"J Yang","year":"2013","unstructured":"Yang J, Chen Y, Li X, et al. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis. Int J Cardiol 2013; 168: 4234-43.","journal-title":"Int J Cardiol"},{"key":"748_CR206","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ijcard.2014.09.174","volume":"177","author":"H Xu","year":"2014","unstructured":"Xu H, Xie X, Wang B, et al. Meta-analysis of efficacy and safety of genotype-guided pharmacogenetic dosing of warfarin. Int J Cardiol 2014; 177: 654-7.","journal-title":"Int J Cardiol"},{"key":"748_CR207","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ijcard.2014.06.031","volume":"175","author":"Q Tang","year":"2014","unstructured":"Tang Q, Zou H, Guo C, Liu Z. Outcomes of pharmacogenetics-guided dosing of warfarin: a systematic review and meta-analysis. Int J Cardiol 2014; 175: 587-91.","journal-title":"Int J Cardiol"},{"key":"748_CR208","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jamainternmed.2014.2368","volume":"174","author":"K Stergiopoulos","year":"2014","unstructured":"Stergiopoulos K, Brown DL. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. JAMA Intern Med 2014; 174: 1330-8.","journal-title":"JAMA Intern Med"},{"key":"748_CR209","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s11239-014-1099-9","volume":"39","author":"Z Liao","year":"2015","unstructured":"Liao Z, Feng S, Ling P, Zhang G. Meta-analysis of randomized controlled trials reveals an improved clinical outcome of using genotype plus clinical algorithm for warfarin dosing. J Thromb Thrombolysis 2015; 39: 228-34.","journal-title":"J Thromb Thrombolysis"},{"key":"748_CR210","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/jth.12647","volume":"12","author":"M Franchini","year":"2014","unstructured":"Franchini M, Mengoli C, Cruciani M, Bonfanti C, Mannucci PM. Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis. J Thromb Haemost 2014; 12: 1480-7.","journal-title":"J Thromb Haemost"},{"key":"748_CR211","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.emc.2014.04.009","volume":"32","author":"R Bhat","year":"2014","unstructured":"Bhat R, Cabey W. Evaluation and management of congenital bleeding disorders. Emerg Med Clin North Am 2014; 32: 673-90.","journal-title":"Emerg Med Clin North Am"},{"key":"748_CR212","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/ajh.23557","volume":"88","author":"N Rydz","year":"2013","unstructured":"Rydz N, Leggo J, Tinlin S, James P, Lillicrap D. The Canadian \u201cNational Program for hemophilia mutation testing\u201d database: a ten-year review. Am J Hematol 2013; 88: 1030-4.","journal-title":"Am J Hematol"},{"issue":"Suppl 4","key":"748_CR213","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/hae.12411","volume":"20","author":"KH High","year":"2014","unstructured":"High KH, Nathwani A, Spencer T, Lillicrap D. Current status of haemophilia gene therapy. Haemophilia 2014; 20(Suppl 4): 43-9.","journal-title":"Haemophilia"},{"issue":"Suppl 4","key":"748_CR214","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/hae.12414","volume":"20","author":"EJ Favaloro","year":"2014","unstructured":"Favaloro EJ, Bodo I, Israels SJ, Brown SA. von Willebrand disease and platelet disorders. Haemophilia 2014; 20(Suppl 4): 59-64.","journal-title":"Haemophilia"},{"key":"748_CR215","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.mcna.2013.07.004","volume":"97","author":"A Orfanakis","year":"2013","unstructured":"Orfanakis A, Deloughery T. Patients with disorders of thrombosis and hemostasis. Med Clin North Am 2013; 97: 1161-80.","journal-title":"Med Clin North Am"},{"issue":"Suppl 4","key":"748_CR216","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2516.2012.02841.x","volume":"18","author":"F Peyvandi","year":"2012","unstructured":"Peyvandi F, Bolton-Maggs PH, Batorova A, De Moerloose P. Rare bleeding disorders. Haemophilia 2012; 18(Suppl 4): 148-53.","journal-title":"Haemophilia"},{"key":"748_CR217","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1182\/blood-2014-08-532820","volume":"125","author":"R Palla","year":"2015","unstructured":"Palla R, Peyvandi F, Shapiro AD. Rare bleeding disorders: diagnosis and treatment. Blood 2015; 125: 2052-61.","journal-title":"Blood"},{"key":"748_CR218","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/j.clinthera.2015.08.021","volume":"37","author":"PM Davidson","year":"2015","unstructured":"Davidson PM, Newton PJ, Tankumpuan T, Paull G, Dennison-Himmelfarb C. Multidisciplinary management of chronic heart failure: principles and future trends. Clin Ther 2015; 37: 2225-33.","journal-title":"Clin Ther"},{"key":"748_CR219","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2459\/JCM.0b013e32833e8b0d","volume":"12","author":"L Mestroni","year":"2011","unstructured":"Mestroni L, Merlo M, Taylor MR, Camerini F, Sinagra G. Heart failure and personalized medicine. J Cardiovasc Med (Hagerstown) 2011; 12: 6-12.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"748_CR220","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-8-201004200-00008","author":"L Wang","year":"2010","unstructured":"Wang L, Seidman JG, Seidman CE. Narrative review: harnessing molecular genetics for the diagnosis and management of hypertrophic cardiomyopathy. Ann Intern Med 2010. DOI: 10.7326\/0003-4819-152-8-201004200-00008 .","journal-title":"Ann Intern Med"},{"key":"748_CR221","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1161\/CIRCULATIONAHA.106.174287","volume":"113","author":"BJ Maron","year":"2006","unstructured":"Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006; 113: 1807-16.","journal-title":"Circulation"},{"key":"748_CR222","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"118","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J Heart 2016; 118: 891-975.","journal-title":"Eur. J Heart"},{"key":"748_CR223","unstructured":"Writing Committee Members; Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: e240-327."},{"key":"748_CR224","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cardfail.2009.01.006","volume":"15","author":"RE Hershberger","year":"2009","unstructured":"Hershberger RE, Lindenfeld J, Mestroni L, et al. Genetic evaluation of cardiomyopathy - a Heart Failure Society of America practice guideline. J Card Fail 2009; 15: 83-97.","journal-title":"J Card Fail"},{"key":"748_CR225","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMc052632","volume":"354","author":"C Meune","year":"2006","unstructured":"Meune C, Van Berlo JH, Anselme F, Bonne G, Pinto YM, Duboc D. Primary prevention of sudden death in patients with lamin A\/C gene mutations. N Engl J Med 2006; 354: 209-10.","journal-title":"N Engl J Med"},{"key":"748_CR226","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/HCO.0b013e3282fcd662","volume":"23","author":"DM McNamara","year":"2008","unstructured":"McNamara DM. Emerging role of pharmacogenomics in heart failure. Curr Opin Cardiol 2008; 23: 261-8.","journal-title":"Curr Opin Cardiol"},{"key":"748_CR227","doi-asserted-by":"crossref","first-page":"11288","DOI":"10.1073\/pnas.0509937103","volume":"103","author":"SB Liggett","year":"2006","unstructured":"Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA 2006; 103: 11288-93.","journal-title":"Proc Natl Acad Sci USA"},{"key":"748_CR228","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCHEARTFAILURE.109.885962","volume":"3","author":"MR Bristow","year":"2010","unstructured":"Bristow MR, Murphy GA, Krause-Steinrauf H, et al. An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail 2010; 3: 21-8.","journal-title":"Circ Heart Fail"},{"key":"748_CR229","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jacc.2006.07.030","volume":"48","author":"DM McNamara","year":"2006","unstructured":"McNamara DM, Tam SW, Sabolinski ML, et al. Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial. J Am Coll Cardiol 2006; 48: 1277-82.","journal-title":"J Am Coll Cardiol"}],"container-title":["Canadian Journal of Anesthesia\/Journal canadien d'anesth\u00e9sie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12630-016-0748-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12630-016-0748-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12630-016-0748-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:15:57Z","timestamp":1718842557000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12630-016-0748-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,17]]},"references-count":229,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["748"],"URL":"https:\/\/doi.org\/10.1007\/s12630-016-0748-1","relation":{},"ISSN":["0832-610X","1496-8975"],"issn-type":[{"value":"0832-610X","type":"print"},{"value":"1496-8975","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,17]]}}}